Literature DB >> 17122517

Nuclear beta-catenin accumulation as reliable marker for the differentiation between cystic craniopharyngiomas and rathke cleft cysts: a clinico-pathologic approach.

Bernd M Hofmann1, Jürgen Kreutzer, Wolfgang Saeger, Michael Buchfelder, Ingmar Blümcke, Rudolf Fahlbusch, Rolf Buslei.   

Abstract

Clinical and histopathologic differentiation of cystic lesions from the sellar region, that is, craniopharyngiomas (CPs) and Rathke cleft cysts (RCCs), is challenging and has paramount importance with respect to variable clinical manifestation and adapted surgical treatment strategies in both entities. Here, we retrospectively evaluated clinico-pathologic findings in 81 patients presenting with a cystic tumor located in the sellar region. All patients underwent transsphenoidal or transcranial resections. Microscopic inspection of surgical specimens identified CP in 51 patients, and RCC in 30 patients. Amongst the panel of immunohistochemical marker proteins used for histopathologic analysis, nuclear accumulation of beta-catenin was detectable only in CP. On the basis of the histopathologic and immunohistochemical analysis, clinical presentation (sex, age, ophthalmologic, and endocrinologic deficits), imaging (tumor location, size, and calcification), as well as a description of cyst contents obtained during operation were retrospectively evaluated. In purely cystic CPs, an isointense signal was more frequent in T1-weighted magnetic resonance images and calcification of the tumor capsule in computed tomography scans. In addition, the size of RCC was smaller and this tumor entity was more often located within the sella. Aberrant (nuclear) immunohistochemical staining for beta-catenin appeared, however, as most reliable factor for the differentiation between purely cystic CPs and RCCs, whereas tumor location, tumor size, and calcification of the tumor capsule were less consistent parameters. The data are compatible with distinct pathogenic pathways associated with these related histopathologic entities.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17122517     DOI: 10.1097/01.pas.0000213328.64121.12

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  32 in total

Review 1.  Childhood craniopharyngioma--current concepts in diagnosis, therapy and follow-up.

Authors:  Hermann L Müller
Journal:  Nat Rev Endocrinol       Date:  2010-09-28       Impact factor: 43.330

Review 2.  Can tissue biomarkers reliably predict the biological behavior of craniopharyngiomas? A comprehensive overview.

Authors:  Ruth Prieto; José M Pascual
Journal:  Pituitary       Date:  2018-08       Impact factor: 4.107

3.  [The 2017 WHO classification of pituitary tumors].

Authors:  Wolfgang Saeger
Journal:  Pathologe       Date:  2021-04-20       Impact factor: 1.011

4.  Targeted BRAF and CTNNB1 next-generation sequencing allows proper classification of nonadenomatous lesions of the sellar region in samples with limiting amounts of lesional cells.

Authors:  Gianluca Marucci; Dario de Biase; Matteo Zoli; Marco Faustini-Fustini; Antonella Bacci; Ernesto Pasquini; Michela Visani; Diego Mazzatenta; Giorgio Frank; Giovanni Tallini
Journal:  Pituitary       Date:  2015-12       Impact factor: 4.107

Review 5.  Pediatric Craniopharyngiomas: A Primer for the Skull Base Surgeon.

Authors:  Christopher Salvatore Graffeo; Avital Perry; Michael J Link; David J Daniels
Journal:  J Neurol Surg B Skull Base       Date:  2018-01-19

6.  Adamantinomatous craniopharyngiomas express tumor stem cell markers in cells with activated Wnt signaling: further evidence for the existence of a tumor stem cell niche?

Authors:  Annett Hölsken; Christina Stache; Sven Martin Schlaffer; Jörg Flitsch; Rudolf Fahlbusch; Michael Buchfelder; Rolf Buslei
Journal:  Pituitary       Date:  2014-12       Impact factor: 4.107

7.  Usefulness of Contrast-Enhanced 3D-FLAIR MR Imaging for Differentiating Rathke Cleft Cyst from Cystic Craniopharyngioma.

Authors:  M Azuma; Z A Khant; M Kitajima; H Uetani; T Watanabe; K Yokogami; H Takeshima; T Hirai
Journal:  AJNR Am J Neuroradiol       Date:  2019-12-19       Impact factor: 3.825

8.  CTNNB1 gene mutations, pituitary transcription factors, and MicroRNA expression involvement in the pathogenesis of adamantinomatous craniopharyngiomas.

Authors:  Marina Lanciotti Campanini; Leandro Machado Colli; Beatriz Maria Carvalho Paixao; Tatiana Pereira Freitas Cabral; Fernando Colbari Amaral; Helio Rubens Machado; Luciano Serafin Neder; Fabiano Saggioro; Ayrton Custodio Moreira; Sonir Roberto Rauber Antonini; Margaret de Castro
Journal:  Horm Cancer       Date:  2010-08       Impact factor: 3.869

9.  Histopathology and molecular characterisation of intrauterine-diagnosed congenital craniopharyngioma.

Authors:  Valeria Scagliotti; Laura Avagliano; Angelica Gualtieri; Federica Graziola; Patrizia Doi; Jane Chalker; Andrea Righini; Marta Korbonits; Gaetano Bulfamante; Thomas S Jacques; Valentina Massa; Carles Gaston-Massuet
Journal:  Pituitary       Date:  2016-02       Impact factor: 4.107

Review 10.  Pathology and pathogenesis of craniopharyngiomas.

Authors:  Sarah J Larkin; Olaf Ansorge
Journal:  Pituitary       Date:  2013-03       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.